Status
Conditions
Treatments
About
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
Patient must have:
Exclusion Criteria
Co-existing Condition:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Concurrent Medication:
Excluded within 2 weeks of study entry:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Prior Medication:
Excluded within 2 weeks of study entry:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal